Sabby Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Sabby Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-547	Closed	-$4.53M	–	155
2018 Q2	$4.53M	Sell	547 -228	-29%	-$17.6K	0.7%	24
2018 Q1	$5.16M	Buy	+775	New	+$44.8K	0.61%	25
2016 Q1	–	Sell	-770	Closed	-$3.49M	–	381
2015 Q4	$3.49M	Sell	770 -632	-45%	-$33.1K	0.19%	82
2015 Q3	$5.85M	Buy	1,402 +504	+56%	+$26.3K	0.24%	70
2015 Q2	$5.41M	Buy	+898	New	+$59.4K	0.2%	85

Other funds holding ONCE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Sabby Management's ONCE Position: Q1 2018 in Review

Sabby Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2018, closing a stake of 110,827 shares — an estimated $6.4M sold.

Sabby Management first reported a position in ONCE in Q4 2017 and held it in 1 quarter. The position peaked at $5.7M in Q4 2017. 162 funds tracked by Wall St. Rank hold ONCE as of Q1 2018.

Sabby Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Sabby Management sold 110,827 Spark Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $6.4M.
Sabby Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
Sabby Management's Spark Therapeutics, Inc. Common Stock position peaked at $5.7M in Q4 2017.
162 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.